Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Open in Screener

HALO

Halozyme Therapeutics Inc

Feb 13 • 04:00PM ET

79.44

+2.52 3.28 %

Healthcare • Biotechnology • USA • NASD

Peers: VRTX BIIB REGN AMGN GILD NBIX INCY ALNY EXEL IONS

| Held by: IJH VTI VB XBI VBK FBT VXF MDY IBB XMHQ

Index	-	P/E	16.70	EPS (ttm)	4.76	Insider Own	1.13%	Shs Outstand	117.52M	Perf Week	-2.20%
Market Cap	9.34B	Forward P/E	9.68	EPS next Y	8.21	Insider Trans	-17.60%	Shs Float	116.26M	Perf Month	8.88%
Enterprise Value	10.15B	PEG	0.31	EPS next Q	2.16	Inst Own	103.99%	Short Float	11.63%	Perf Quarter	12.47%
Income	595.49M	P/S	7.52	EPS this Y	51.34%	Inst Trans	2.12%	Short Ratio	6.52	Perf Half Y	21.21%
Sales	1.24B	P/B	18.53	EPS next Y	28.20%	ROA	27.45%	Short Interest	13.52M	Perf YTD	18.04%
Book/sh	4.29	P/C	13.31	EPS next 5Y	31.70%	ROE	124.50%	52W High	82.22 -3.38%	Perf Year	35.54%
Cash/sh	5.97	P/FCF	15.51	EPS past 3/5Y	7.74% -	ROIC	45.67%	52W Low	47.50 67.24%	Perf 3Y	61.79%
Dividend Est.	-	EV/EBITDA	12.39	Sales past 3/5Y	31.82% 38.95%	Gross Margin	78.83%	Volatility	3.10% 3.27%	Perf 5Y	59.39%
Dividend TTM	-	EV/Sales	8.17	EPS Y/Y TTM	59.01%	Oper. Margin	59.33%	ATR (14)	2.45	Perf 10Y	953.58%
Dividend Ex-Date	-	Quick Ratio	1.37	Sales Y/Y TTM	31.19%	Profit Margin	47.91%	RSI (14)	62.78	Recom	2.00
Dividend Gr. 3/5Y	- -	Current Ratio	1.59	EPS Q/Q	36.06%	SMA20	6.14%	Beta	0.96	Target Price	78.00
Payout	0.00%	Debt/Eq	3.00	Sales Q/Q	22.12%	SMA50	12.63%	Rel Volume	0.84	Prev Close	76.92
Employees	350	LT Debt/Eq	1.59	Earnings	Feb 17 AMC	SMA200	21.22%	Avg Volume	2.07M	Price	79.44
IPO	Mar 12, 2004	Option/Short	Yes / Yes	EPS/Sales Surpr.	5.51% 4.19%	Trades		Volume	1,735,479	Change	3.28%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-04-25	Downgrade	Goldman	Neutral → Sell	$56
Oct-14-25	Upgrade	Leerink Partners	Underperform → Market Perform	$70
Aug-06-25	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$75
Jul-10-25	Resumed	Goldman	Neutral	$55
May-14-25	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$62
May-13-25	Downgrade	Leerink Partners	Market Perform → Underperform	$47
Oct-07-24	Downgrade	Wells Fargo	Overweight → Equal Weight	$58 → $62
Sep-19-24	Downgrade	JP Morgan	Overweight → Neutral	$52 → $57
Jun-07-24	Downgrade	Piper Sandler	Overweight → Neutral	$48 → $51
Feb-29-24	Initiated	TD Cowen	Outperform	$54
Jul-24-23	Initiated	H.C. Wainwright	Buy	$61
Jul-24-23	Downgrade	Goldman	Buy → Neutral	$43 → $45
May-10-23	Upgrade	Piper Sandler	Neutral → Overweight	$46
Mar-27-23	Resumed	Berenberg	Buy	$58
Mar-16-23	Downgrade	SVB Securities	Outperform → Market Perform	$42
Dec-21-22	Resumed	Morgan Stanley	Overweight	$53 → $65
Nov-28-22	Initiated	Wells Fargo	Overweight	$65
Sep-09-22	Initiated	Morgan Stanley	Overweight	$50
May-23-22	Initiated	SVB Leerink	Outperform	$52
Jun-14-21	Initiated	Evercore ISI	Outperform

Show Previous Ratings

Feb-13-26 09:15AM	Stay Ahead of the Game With Halozyme Therapeutics (HALO) Q4 Earnings: Wall Street's Insights on Key Metrics (Zacks)
Feb-11-26 10:00AM	Earnings Preview: BioMarin Pharmaceutical (BMRN) Q4 Earnings Expected to Decline (Zacks)
Feb-10-26 04:05PM	Halozyme to Report Fourth Quarter and Full Year 2025 Financial and Operating Results (PR Newswire)
11:15AM	Biotech: Halozyme CEO explains what it looks for in M&A targets (Yahoo Finance Video)
10:00AM	Halozyme Therapeutics (HALO) to Report Q4 Results: Wall Street Expects Earnings Growth (Zacks)
09:57AM	Loading…
Feb-05-26 09:57AM	This Medical Technology Leader Sees Growth Into The 2040s (Investor's Business Daily)
Feb-04-26 06:09PM	Silicon Motion Moves Higher On Rosy Outlook (Investor's Business Daily)
10:39AM	Google Stock: What The Buy Side Expects From Cloud Computing Business (Investor's Business Daily)
09:40AM	Why Halozyme Therapeutics (HALO) is a Top Value Stock for the Long-Term (Zacks)
08:21AM	Stock Market Today: Dow Rises Ahead Of Jobs Data; AMD Plunges On Earnings (Live Coverage) (Investor's Business Daily)
Feb-03-26 04:57PM	Stock Market Today: Nasdaq Gets Hit Hardest As Techs Sink; Palantir Climbs After Earnings (Live Coverage) (Investor's Business Daily)
08:55AM	How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings (Zacks)
Feb-02-26 05:33PM	IBD Stock Of The Day Halozyme Eyes Two Buy Points; How It's 'Layering' Up For Future Growth (Investor's Business Daily)
12:10PM	Will Halozyme Therapeutics (HALO) Beat Estimates Again in Its Next Earnings Report? (Zacks)
Jan-31-26 08:00AM	5 Stocks To Watch Trade Near Buy Points; Three Are Data Center Plays (Investor's Business Daily)
09:50AM	Loading…
Jan-30-26 09:50AM	Why Halozyme Therapeutics (HALO) is a Top Momentum Stock for the Long-Term (Zacks)
08:30AM	If You Invested $1000 in Halozyme Therapeutics a Decade Ago, This is How Much It'd Be Worth Now (Zacks)
Jan-29-26 01:25PM	H.C. Wainwright Sees Strength in Halozyme Therapeutics' ENHANZE Platform, Reiterates Buy Rating (Insider Monkey)
11:52AM	HALO Rises Nearly 4% on Strong 2025 Preliminary Data and 2026 Guidance (Zacks)
Jan-28-26 01:58PM	Halozyme Therapeutics Projects Sustained Growth Well Into 2040 (Benzinga)
12:02PM	Halozyme Therapeutics Raises 2026 Guidance After Hypercon, Surf Bio Deals Extend Platform Into 2040s (MarketBeat)
06:30AM	Halozyme Raises 2025 Revenue Estimates, Raises 2026 and Multi-Year Financial Guidance (PR Newswire)
06:20AM	Halozyme buys a biotech startup; Cytokinetics launches heart drug (BioPharma Dive)
Jan-24-26 02:20PM	2 Under-the-Radar Biotech Stocks Set to Boom in 2026 (Motley Fool)
Jan-22-26 09:52PM	TD Cowen Notes Shifting Positive Sentiment for Halozyme (HALO) Ahead of Q4 Earnings, 2026 Guidance (Insider Monkey)
Jan-20-26 04:05PM	Halozyme to Host Investor Conference Call to Provide Updated Financial Guidance and Business Update (PR Newswire)
02:38PM	Halozyme (HALO) Boosted by ENHANZE Launches and Analyst Upgrade (Insider Monkey)
Jan-19-26 07:20PM	Halozyme Therapeutics: A 6.3 Rating and a Future Full of Uncertainty (Motley Fool)
Jan-18-26 10:36PM	Q3 Therapeutics Earnings: Halozyme Therapeutics (NASDAQ:HALO) Earns Top Marks (StockStory)
Jan-15-26 01:23PM	Oric Pharmaceuticals Stock Sees Healthy RS Rating Jump To 80 (Investor's Business Daily)
09:50AM	Loading…
Jan-13-26 09:50AM	Halozyme Therapeutics (HALO) is a Top-Ranked Momentum Stock: Should You Buy? (Zacks)
Jan-12-26 09:40AM	Are Medical Stocks Lagging Ardelyx (ARDX) This Year? (Zacks)
Jan-09-26 11:40AM	HALO or AXSM: Which Is the Better Value Stock Right Now? (Zacks)
Jan-08-26 09:40AM	Are You a Value Investor? This 1 Stock Could Be the Perfect Pick (Zacks)
08:00AM	Halozyme Announces Global Collaboration and License Agreement with Takeda to Develop and Commercialize Vedolizumab with ENHANZE (PR Newswire)
Jan-07-26 11:04PM	Halozyme Therapeutics (HALO): Buy, Sell, or Hold Post Q3 Earnings? (StockStory)
11:25AM	Smorgasbord Of Buy Points Kicks Off 2026. Google, Nvidia On The Menu. (Investor's Business Daily)
Jan-06-26 09:38AM	CoreWeave initiated, Shopify downgraded: Wall Street's top analyst calls (The Fly)
Jan-05-26 07:00AM	Halozyme and Skye Bioscience Announce Global Collaboration and License Agreement to Evaluate Nimacimab Co-Formulated with ENHANZE for Obesity (PR Newswire)
Jan-01-26 03:30PM	Halozyme Therapeutics (NASDAQ:HALO) Reports Bullish Q3 CY2025 (StockStory)
Dec-31-25 11:41AM	Here's What Analysts Think About Halozyme Therapeutics (HALO) (Insider Monkey)
Dec-23-25 12:46PM	Halozyme Therapeutics Stock Sees Relative Strength Rating (Investor's Business Daily)
03:53AM	J&J Wins FDA Nod for Subcutaneous Version of NSCLC Drug Rybrevant (Revised) (Zacks)
Dec-19-25 09:40AM	Here's Why Halozyme Therapeutics (HALO) is a Strong Value Stock (Zacks)
Dec-18-25 12:48PM	J&J Wins FDA Nod for Subcutaneous Version of NSCLC Drug Rybrevant (Zacks)
07:00AM	U.S. FDA Approves RYBREVANT FASPRO (amivantamab and hyaluronidase-lpuj) Co-Formulated with ENHANZE for the Treatment of Advanced EGFR-mutated Non-Small Cell Lung Cancer (PR Newswire)
Dec-16-25 01:17PM	Immunotherapy Breakthroughs Turn Cold GI Tumors Hot as Market Tops $443B (PR Newswire)
Dec-09-25 09:45AM	Why Halozyme Therapeutics (HALO) is a Top Growth Stock for the Long-Term (Zacks)
Dec-08-25 04:05PM	Jim Lang Elected to Halozyme's Board of Directors (PR Newswire)
Dec-06-25 09:50AM	The Healthcare Sector Is Surging. Here's 1 Stock Every Investor Should Have on Their Radar. (Motley Fool)
Dec-05-25 09:56AM	Toast upgraded, PayPal downgraded: Wall Streets top analyst calls (TipRanks)
Dec-04-25 02:22PM	Halozyme Granted Injunction Against Merck & Co. in Germany in Keytruda Patent Case (The Wall Street Journal)
01:26PM	Halozyme Wins Preliminary Injunction Against Merck's Keytruda SC in Germany (PR Newswire)
09:53AM	Toast upgraded, PayPal downgraded: Wall Street's top analyst calls (The Fly)
Dec-03-25 12:02PM	AppLovin Stock Rides Swarm Of Setups Beyond Just Mining, Medical Names (Investor's Business Daily)
11:30AM	Why Is Halozyme Therapeutics (HALO) Down 2.2% Since Last Earnings Report? (Zacks)
Dec-01-25 12:00PM	What Makes Halozyme Therapeutics (HALO) a New Buy Stock (Zacks)
08:30AM	If You Invested $1000 in Halozyme Therapeutics a Decade Ago, This is How Much It'd Be Worth Now (Zacks)
08:04AM	Meridian Growth Fund Trimmed Halozyme Therapeutics, Inc. (HALO) Following Appreciation (Insider Monkey)
Nov-27-25 09:40AM	Why Halozyme Therapeutics (HALO) is a Top Value Stock for the Long-Term (Zacks)
09:07AM	This Biotech Stock Is Up 50% in 2025, But Redditors Say It Has More Upside - Here's Why (Insider Monkey)
Nov-25-25 08:30AM	Halozyme to Participate in the 8th Annual Evercore Healthcare Conference (PR Newswire)
Nov-21-25 08:05AM	This Medical Technology Leader Sees Profit Growth Topping 44% (Investor's Business Daily)
Nov-18-25 08:50AM	Halozyme Completes Acquisition of Elektrofi, Expanding Breadth of Offerings in Drug Delivery (PR Newswire)
Nov-17-25 01:17PM	Edgewise Therapeutics Stock Earns RS Rating Upgrade (Investor's Business Daily)
08:45AM	Why I Keep Buying These 10 Incredible Growth Stocks (Motley Fool)
07:00AM	Merus and Halozyme Enter Global Collaboration and License Agreement to Develop Subcutaneous Formulation of Petosemtamab (PR Newswire)
Nov-12-25 02:43PM	Halozyme Stock Surging On Recent Earnings Beat; Record High Ahead? (Investor's Business Daily)
09:50AM	Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick (Zacks)
Nov-11-25 09:40AM	Are You a Value Investor? This 1 Stock Could Be the Perfect Pick (Zacks)
Nov-07-25 01:20PM	Halozyme Therapeutics Stock Sees Improved RS Rating (Investor's Business Daily)
08:30AM	FDA Approved DARZALEX Faspro for Adult Patients with High-Risk Smoldering Multiple Myeloma (PR Newswire)
Nov-06-25 11:37PM	Halozyme Therapeutics, Inc. Announces Pricing of Private Offering of $650 Million of Convertible Senior Notes due 2031 and $650 Million of Convertible Senior Notes due 2032 (PR Newswire)
Nov-05-25 04:05PM	Halozyme Therapeutics, Inc. Announces Proposed Offering of $650 Million of Convertible Senior Notes due 2031 and $650 Million of Convertible Senior Notes due 2032 (PR Newswire)
Nov-04-25 10:31AM	Halozyme Beats on Q3 Earnings & Revenues, Raises 2025 View (Zacks)
12:01AM	Halozyme Therapeutics Inc (HALO) Q3 2025 Earnings Call Highlights: Record Royalty Revenue and ... (GuruFocus.com)
Nov-03-25 06:30PM	Halozyme Therapeutics (HALO) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
05:35PM	Halozyme Therapeutics (HALO) Beats Q3 Earnings and Revenue Estimates (Zacks)
04:37PM	Halozyme Therapeutics: Q3 Earnings Snapshot (Associated Press Finance)
04:01PM	HALOZYME RAISES 2025 FINANCIAL GUIDANCE AND REPORTS STRONG THIRD QUARTER 2025 FINANCIAL AND OPERATING RESULTS (PR Newswire)
Oct-28-25 12:24PM	H.C. Wainwright Maintains a Buy on Halozyme Therapeutics (HALO), Keeps the PT at $90 (Insider Monkey)
10:00AM	AnaptysBio, Inc. (ANAB) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release (Zacks)
Oct-27-25 12:45PM	Is Halozyme Stock a Portfolio Must-Have Ahead of Q3 Earnings? (Zacks)
10:00AM	Halozyme Therapeutics (HALO) Earnings Expected to Grow: What to Know Ahead of Next Week's Release (Zacks)
Oct-23-25 10:01AM	Will Higher Royalties From Partners Fuel HALO's Growth in H2 2025? (Zacks)
Oct-22-25 08:50AM	How to Find Strong Medical Stocks Slated for Positive Earnings Surprises (Zacks)
Oct-21-25 08:50AM	Why Investors Need to Take Advantage of These 2 Medical Stocks Now (Zacks)
08:30AM	Halozyme to Report Third Quarter 2025 Financial and Operating Results (PR Newswire)
Oct-20-25 12:10PM	Will Halozyme Therapeutics (HALO) Beat Estimates Again in Its Next Earnings Report? (Zacks)
Oct-17-25 09:40AM	Here's Why Halozyme Therapeutics (HALO) is a Strong Value Stock (Zacks)
Oct-16-25 01:51PM	Halozyme Rallies Almost 40% YTD: How Should You Play the Stock? (Zacks)
01:40PM	Xencor Stock Earns Relative Strength Rating Upgrade (Investor's Business Daily)
Oct-08-25 01:05PM	Scholar Rock Holding Stock Scores RS Rating Upgrade (Investor's Business Daily)
10:49AM	Can Elektrofi Acquisition Drive Halozyme's Long-Term Growth? (Zacks)
Oct-06-25 09:40AM	Are Medical Stocks Lagging Armata Pharmaceuticals (ARMP) This Year? (Zacks)
Oct-02-25 09:50AM	Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio (Zacks)
07:25AM	Halozyme eyes microparticles in $900m Elektrofi acquisition (Pharmaceutical Technology)
01:35AM	Benchmark Sees More Upside for Halozyme Therapeutics (HALO), Hikes Price Target (Insider Monkey)
Oct-01-25 07:00AM	Halozyme to Acquire Elektrofi, Expanding Our Offerings in Innovative Drug Delivery and Strengthening Long-Term Growth into 2040s (PR Newswire)
06:00AM	FDA officials comments spark Aurinia sell-off; Halozyme buys a biotech (BioPharma Dive)

Halozyme Therapeutics, Inc. is a biopharmaceutical technology platform company. It engages in developing, manufacturing, and commercializing drug-device combination products using advanced auto-injector technology that are designed to provide commercial or functional advantages such as improved convenience and tolerability, and enhanced patient comfort and adherence. The company was founded by Gregory Ian Frost on February 26, 1998 and is headquartered in San Diego, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Torley Helen	PRESIDENT AND CEO	Feb 03 '26	Option Exercise	12.07	20,000	241,400	728,719	Feb 05 07:38 PM
Torley Helen	PRESIDENT AND CEO	Feb 04 '26	Option Exercise	12.07	20,000	241,400	728,719	Feb 05 07:38 PM
Torley Helen	PRESIDENT AND CEO	Feb 05 '26	Option Exercise	12.07	10,000	120,700	718,719	Feb 05 07:38 PM
Torley Helen	PRESIDENT AND CEO	Feb 04 '26	Sale	77.24	20,000	1,544,820	708,719	Feb 05 07:38 PM
Torley Helen	PRESIDENT AND CEO	Feb 03 '26	Sale	76.12	20,000	1,522,317	708,719	Feb 05 07:38 PM
Torley Helen	PRESIDENT AND CEO	Feb 05 '26	Sale	78.64	10,000	786,366	708,719	Feb 05 07:38 PM
Helen Torley	President, CEO, Director	Feb 03 '26	Proposed Sale	74.45	150,000	11,167,500		Feb 03 04:17 PM
Connaughton Bernadette	Director	Jan 05 '26	Sale	70.25	2,000	140,500	40,123	Jan 06 06:55 PM
Snyder Mark Howard	SVP, CHIEF LEGAL OFFICER	Jan 03 '26	Option Exercise	0.00	7,611	0	38,424	Jan 06 06:55 PM
BERNADETTE CONNAUGHTON	Director	Jan 05 '26	Proposed Sale	70.31	2,000	140,620		Jan 05 04:39 PM
Caudill Cortney	SVP, CHIEF OPERATING OFFICER	Nov 01 '25	Option Exercise	0.00	9,326	0	17,000	Dec 19 05:39 PM
Caudill Cortney	SVP, CHIEF OPERATING OFFICER	Nov 01 '25	Sale	65.19	4,263	277,905	12,737	Dec 19 05:39 PM
Connaughton Bernadette	Director	Dec 01 '25	Sale	71.60	829	59,356	42,123	Dec 01 07:50 PM
Torley Helen	PRESIDENT AND CEO	Dec 01 '25	Option Exercise	8.11	16,569	134,375	725,288	Dec 01 07:31 PM
Torley Helen	PRESIDENT AND CEO	Dec 01 '25	Sale	68.92	16,569	1,141,925	708,719	Dec 01 07:31 PM
Torley Helen	PRESIDENT AND CEO	Nov 10 '25	Option Exercise	8.11	20,000	162,200	753,719	Nov 12 06:54 PM
Torley Helen	PRESIDENT AND CEO	Nov 11 '25	Option Exercise	8.11	20,000	162,200	753,719	Nov 12 06:54 PM
Torley Helen	PRESIDENT AND CEO	Nov 12 '25	Option Exercise	8.11	20,000	162,200	753,719	Nov 12 06:54 PM
Torley Helen	PRESIDENT AND CEO	Nov 12 '25	Sale	70.55	20,000	1,410,990	733,719	Nov 12 06:54 PM
Torley Helen	PRESIDENT AND CEO	Nov 11 '25	Sale	69.13	20,000	1,382,600	733,719	Nov 12 06:54 PM
Torley Helen	PRESIDENT AND CEO	Nov 10 '25	Sale	68.72	20,000	1,374,339	733,719	Nov 12 06:54 PM
Connaughton Bernadette	Director	Nov 10 '25	Sale	68.48	2,000	136,960	42,952	Nov 12 05:58 PM
Torley Helen	PRESIDENT AND CEO	Oct 01 '25	Option Exercise	8.11	20,000	162,200	753,719	Oct 03 06:00 PM
Torley Helen	PRESIDENT AND CEO	Oct 03 '25	Option Exercise	8.11	20,000	162,200	753,719	Oct 03 06:00 PM
Torley Helen	PRESIDENT AND CEO	Oct 02 '25	Option Exercise	8.11	20,000	162,200	753,719	Oct 03 06:00 PM
Torley Helen	PRESIDENT AND CEO	Oct 01 '25	Sale	75.35	20,000	1,507,024	733,719	Oct 03 06:00 PM
Torley Helen	PRESIDENT AND CEO	Oct 02 '25	Sale	71.20	20,000	1,424,083	733,719	Oct 03 06:00 PM
Torley Helen	PRESIDENT AND CEO	Oct 03 '25	Sale	69.03	20,000	1,380,638	733,719	Oct 03 06:00 PM
Connaughton Bernadette	Director	Oct 01 '25	Sale	75.24	2,000	150,481	44,952	Oct 01 06:29 PM
Helen Torley	President, CEO, Director	Oct 01 '25	Proposed Sale	73.34	136,569	10,015,970		Oct 01 04:26 PM
LaBrosse Nicole	SVP, CHIEF FINANCIAL OFFICER	Sep 22 '25	Sale	77.95	2,227	173,584	22,079	Sep 23 04:15 PM
LaBrosse Nicole	SVP, CHIEF FINANCIAL OFFICER	Sep 10 '25	Option Exercise	12.11	12,406	150,217	44,306	Sep 11 05:09 PM
LaBrosse Nicole	SVP, CHIEF FINANCIAL OFFICER	Sep 10 '25	Sale	75.71	20,000	1,514,267	24,306	Sep 11 05:09 PM
NICOLE LABROSSE	Officer	Sep 10 '25	Proposed Sale	76.07	22,227	1,690,808		Sep 10 04:37 PM
Torley Helen	PRESIDENT AND CEO	Sep 02 '25	Option Exercise	8.11	20,000	162,200	753,719	Sep 04 05:41 PM
Torley Helen	PRESIDENT AND CEO	Sep 03 '25	Option Exercise	8.11	20,000	162,200	753,719	Sep 04 05:41 PM
Torley Helen	PRESIDENT AND CEO	Sep 04 '25	Option Exercise	8.11	20,000	162,200	753,719	Sep 04 05:41 PM
Torley Helen	PRESIDENT AND CEO	Sep 03 '25	Sale	74.44	20,000	1,488,726	733,719	Sep 04 05:41 PM
Torley Helen	PRESIDENT AND CEO	Sep 04 '25	Sale	74.04	20,000	1,480,772	733,719	Sep 04 05:41 PM
Torley Helen	PRESIDENT AND CEO	Sep 02 '25	Sale	73.76	20,000	1,475,128	733,719	Sep 04 05:41 PM
Connaughton Bernadette	Director	Sep 02 '25	Sale	73.68	4,000	294,736	46,952	Sep 02 08:11 PM
BERNADETTE CONNAUGHTON	Director	Sep 02 '25	Proposed Sale	73.15	8,829	645,841		Sep 02 04:38 PM
Torley Helen	PRESIDENT AND CEO	Aug 11 '25	Option Exercise	8.11	20,000	162,200	753,719	Aug 13 06:22 PM
Torley Helen	PRESIDENT AND CEO	Aug 12 '25	Option Exercise	8.11	20,000	162,200	753,719	Aug 13 06:22 PM
Torley Helen	PRESIDENT AND CEO	Aug 13 '25	Option Exercise	8.11	20,000	162,200	753,719	Aug 13 06:22 PM
Torley Helen	PRESIDENT AND CEO	Aug 13 '25	Sale	64.32	20,000	1,286,351	733,719	Aug 13 06:22 PM
Torley Helen	PRESIDENT AND CEO	Aug 12 '25	Sale	63.51	20,000	1,270,121	733,719	Aug 13 06:22 PM
Torley Helen	PRESIDENT AND CEO	Aug 11 '25	Sale	63.05	20,000	1,260,917	733,719	Aug 13 06:22 PM
Torley Helen	PRESIDENT AND CEO	Jul 08 '25	Option Exercise	8.11	20,000	162,200	753,719	Jul 10 07:43 PM
Torley Helen	PRESIDENT AND CEO	Jul 09 '25	Option Exercise	8.11	20,000	162,200	753,719	Jul 10 07:43 PM
Torley Helen	PRESIDENT AND CEO	Jul 10 '25	Option Exercise	8.11	20,000	162,200	753,719	Jul 10 07:43 PM
Torley Helen	PRESIDENT AND CEO	Jul 10 '25	Sale	57.43	20,000	1,148,618	733,719	Jul 10 07:43 PM
Torley Helen	PRESIDENT AND CEO	Jul 09 '25	Sale	56.43	20,000	1,128,655	733,719	Jul 10 07:43 PM
Torley Helen	PRESIDENT AND CEO	Jul 08 '25	Sale	55.51	20,000	1,110,245	733,719	Jul 10 07:43 PM
Torley Helen	PRESIDENT AND CEO	Jun 20 '25	Option Exercise	8.11	20,000	162,200	753,719	Jun 24 05:40 PM
Torley Helen	PRESIDENT AND CEO	Jun 24 '25	Option Exercise	8.11	20,000	162,200	753,719	Jun 24 05:40 PM
Torley Helen	PRESIDENT AND CEO	Jun 23 '25	Option Exercise	8.11	20,000	162,200	753,719	Jun 24 05:40 PM
Torley Helen	PRESIDENT AND CEO	Jun 24 '25	Sale	53.73	20,000	1,074,620	733,719	Jun 24 05:40 PM
Torley Helen	PRESIDENT AND CEO	Jun 20 '25	Sale	52.96	20,000	1,059,200	733,719	Jun 24 05:40 PM
Torley Helen	PRESIDENT AND CEO	Jun 23 '25	Sale	52.57	20,000	1,051,460	733,719	Jun 24 05:40 PM
Helen Torley	President, CEO, Director	Jun 20 '25	Proposed Sale	53.15	240,000	12,756,000		Jun 20 04:25 PM
Snyder Mark Howard	SVP, CHIEF LEGAL OFFICER	Jun 12 '25	Option Exercise	0.00	5,035	0	33,524	Jun 13 05:33 PM
Henderson Jeffrey William	Director	Apr 28 '25	Sale	60.37	4,497	271,467	28,611	Apr 28 06:04 PM
Henderson Jeffrey William	Director	Apr 01 '25	Sale	64.05	503	32,217	33,108	Apr 01 06:32 PM
Henderson Jeffrey William	Director	Mar 03 '25	Sale	58.69	5,000	293,458	33,611	Mar 03 08:46 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Feb 26 '25	Sale	58.12	10,000	581,244	175,453	Feb 27 06:32 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Feb 25 '25	Sale	58.05	10,000	580,534	185,453	Feb 27 06:32 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Feb 27 '25	Sale	58.28	1,697	98,902	173,756	Feb 27 06:32 PM
MICHAEL LABARRE	Officer	Feb 25 '25	Proposed Sale	58.50	21,697	1,269,274		Feb 25 04:32 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Feb 23 '25	Option Exercise	0.00	4,747	0	197,863	Feb 24 05:11 PM
Snyder Mark Howard	SVP, CHIEF LEGAL OFFICER	Feb 23 '25	Option Exercise	0.00	7,012	0	32,264	Feb 24 05:07 PM
LaBrosse Nicole	SVP, CHIEF FINANCIAL OFFICER	Feb 23 '25	Option Exercise	0.00	6,688	0	35,501	Feb 24 05:04 PM
Torley Helen	PRESIDENT AND CEO	Feb 23 '25	Option Exercise	0.00	22,436	0	745,800	Feb 24 05:01 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Feb 16 '25	Option Exercise	0.00	31,266	0	196,729	Feb 18 06:42 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Feb 15 '25	Option Exercise	0.00	3,386	0	177,142	Feb 18 06:42 PM
Snyder Mark Howard	SVP, CHIEF LEGAL OFFICER	Feb 16 '25	Option Exercise	0.00	22,205	0	32,411	Feb 18 06:41 PM
LaBrosse Nicole	SVP, CHIEF FINANCIAL OFFICER	Feb 16 '25	Option Exercise	0.00	27,831	0	33,402	Feb 18 06:39 PM
LaBrosse Nicole	SVP, CHIEF FINANCIAL OFFICER	Feb 15 '25	Option Exercise	0.00	1,254	0	16,734	Feb 18 06:39 PM
Torley Helen	PRESIDENT AND CEO	Feb 16 '25	Option Exercise	0.00	109,694	0	744,548	Feb 18 06:37 PM
Torley Helen	PRESIDENT AND CEO	Feb 15 '25	Option Exercise	0.00	13,092	0	679,836	Feb 18 06:37 PM

Open in Screener

BDX

Becton Dickinson & Co

Feb 13 • 04:00PM ET

175.89

-1.92 -1.08 %

Healthcare • Medical Instruments & Supplies • USA • NYSE

BDX Becton Dickinson & Co daily Stock Chart

Peers: JNJ ABT DHR BAX TMO ISRG HOLX BSX ALGN XRAY

| Held by: VTI VOO VO IVV SPY VTV XLV VOE VIG VYM

Index	S&P 500	P/E	28.73	EPS (ttm)	6.12	Insider Own	0.17%	Shs Outstand	284.74M	Perf Week	6.57%
Market Cap	50.08B	Forward P/E	16.11	EPS next Y	10.92	Insider Trans	-0.77%	Shs Float	284.26M	Perf Month	7.91%
Enterprise Value	68.59B	PEG	17.70	EPS next Q	2.25	Inst Own	93.82%	Short Float	2.35%	Perf Quarter	16.50%
Income	1.76B	P/S	2.28	EPS this Y	-9.08%	Inst Trans	2.35%	Short Ratio	2.40	Perf Half Y	14.78%
Sales	21.92B	P/B	1.98	EPS next Y	6.12%	ROA	3.21%	Short Interest	6.69M	Perf YTD	15.33%
Book/sh	88.79	P/C	48.39	EPS next 5Y	0.91%	ROE	6.96%	52W High	184.94 -4.90%	Perf Year	-0.53%
Cash/sh	3.63	P/FCF	19.04	EPS past 3/5Y	-0.35% 16.45%	ROIC	4.16%	52W Low	127.54 37.91%	Perf 3Y	-9.48%
Dividend Est.	3.13 (1.78%)	EV/EBITDA	12.34	Sales past 3/5Y	4.99% 6.32%	Gross Margin	46.07%	Volatility	4.63% 2.86%	Perf 5Y	-10.44%
Dividend TTM	3.28 (1.86%)	EV/Sales	3.13	EPS Y/Y TTM	1.52%	Oper. Margin	14.77%	ATR (14)	5.01	Perf 10Y	64.20%
Dividend Ex-Date	Mar 10, 2026	Quick Ratio	0.58	Sales Y/Y TTM	6.22%	Profit Margin	8.01%	RSI (14)	67.23	Recom	2.33
Dividend Gr. 3/5Y	6.13% 5.65%	Current Ratio	1.05	EPS Q/Q	28.08%	SMA20	7.18%	Beta	0.24	Target Price	153.81
Payout	71.53%	Debt/Eq	0.77	Sales Q/Q	1.63%	SMA50	10.61%	Rel Volume	1.14	Prev Close	177.81
Employees	72000	LT Debt/Eq	0.67	Earnings	Feb 09 BMO	SMA200	19.32%	Avg Volume	2.78M	Price	175.89
IPO	Sep 25, 1963	Option/Short	Yes / Yes	EPS/Sales Surpr.	3.48% -12.84%	Trades		Volume	3,167,399	Change	-1.08%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-10-26	Resumed	Barclays	Overweight	$202
Feb-03-26	Resumed	Citigroup	Buy	$233
Sep-25-25	Initiated	RBC Capital Mkts	Sector Perform	$211
May-22-25	Downgrade	Citigroup	Buy → Neutral	$185
May-02-25	Downgrade	Raymond James	Outperform → Mkt Perform
May-02-25	Downgrade	Piper Sandler	Overweight → Neutral	$185
May-02-25	Downgrade	Goldman	Buy → Neutral	$192
May-01-25	Downgrade	William Blair	Outperform → Mkt Perform
May-01-25	Downgrade	Wells Fargo	Overweight → Equal Weight
May-01-25	Downgrade	BofA Securities	Buy → Neutral	$190
Oct-01-24	Upgrade	Citigroup	Neutral → Buy	$255 → $275
May-30-24	Initiated	Goldman	Buy	$274
Jul-24-23	Upgrade	Raymond James	Mkt Perform → Outperform	$305
May-30-23	Resumed	Morgan Stanley	Overweight	$295
May-05-23	Upgrade	Piper Sandler	Neutral → Overweight	$260 → $290
Apr-12-23	Upgrade	KeyBanc Capital Markets	Sector Weight → Overweight	$304
Jan-03-23	Upgrade	BofA Securities	Neutral → Buy	$250 → $290
Dec-12-22	Upgrade	Citigroup	Sell → Neutral	$221 → $250
Jul-11-22	Downgrade	Citigroup	Neutral → Sell	$265 → $235
Jun-24-22	Upgrade	Wells Fargo	Equal Weight → Overweight	$275

Show Previous Ratings

Feb-13-26 08:48AM	Citi Raises Becton Dickinson (BDX) PT to $198 after Life Sciences Sale Update (Insider Monkey)
Feb-12-26 06:00PM	Al Gore's Strategic Exit from Becton Dickinson & Co: A 13F Filing Insight (GuruFocus.com)
Feb-11-26 01:34PM	BD Merges Biosciences & Diagnostics Business With Waters (Zacks) +5.21%
08:38AM	Are Wall Street Analysts Bullish on Becton, Dickinson and Company Stock? (Barchart)
08:11AM	Waters resumed with an In Line at Evercore ISI (TipRanks)
07:38PM	Loading…
Feb-10-26 07:38PM	Analyst Report: Becton, Dickinson and Company (Morningstar Research) +5.34%
02:17PM	What's Going On With Becton Dickinson Stock Tuesday? (Benzinga)
01:11PM	Dow Jones Reaches Record Highs, Software Stocks Extend Rebound: What's Moving Markets Tuesday? (Benzinga)
01:00PM	Becton, Dickinson and Company Announces Tender Offers for Outstanding Debt Securities (PR Newswire)
10:58AM	Jim Cramer on Becton, Dickinson: "I Kind of Really Like the New Company" (Insider Monkey)
09:45AM	Under Armour cut to Sell, Snap upgraded: Wall Street's top analyst calls (The Fly)
08:10AM	BD shares fall by 3% after lowering FY26 profit outlook (Medical Device Network)
12:34AM	BDX Q4 Deep Dive: Portfolio Reshaping and Product Investments Offset Tariff Headwinds (StockStory)
Feb-09-26 04:34PM	Stocks Settle Higher on Strength in Tech (Barchart)
02:01PM	Becton Dickinson & Co (BDX) Q1 2026 Earnings Call Highlights: Strong Performance Amid ... (GuruFocus.com)
12:05PM	Loading…
12:05PM	Analyst Report: Becton, Dickinson and Company (Morningstar Research)
11:19AM	Waters Q4 Earnings Call Highlights (MarketBeat)
10:38AM	BD Stock Dips in Pre-Market Despite Q1 Earnings Beat, Margins Up (Zacks)
10:06AM	Becton, Dickinson and Company Q1 Earnings Call Highlights (MarketBeat)
10:01AM	Stocks Slip Ahead of this Week's US News on Jobs and Inflation (Barchart)
09:51AM	Waters forecasts first-quarter profit below Wall Street estimates, shares slide (Reuters)
09:23AM	Becton Dickinson Slashes Profit Outlook Post-Spinoff (Benzinga)
08:40AM	Waters Completes Combination with BD's Biosciences & Diagnostic Solutions Businesses (PR Newswire)
08:40AM	BD Completes Combination of Biosciences & Diagnostic Solutions Business with Waters Corporation (PR Newswire)
07:40AM	Becton Dickinson (BDX) Beats Q1 Earnings and Revenue Estimates (Zacks)
06:43AM	BD (NYSE:BDX) Surprises With Q4 CY2025 Sales (StockStory)
06:37AM	Becton Dickinson: Fiscal Q1 Earnings Snapshot (Associated Press Finance)
06:30AM	BD Reports First Quarter Fiscal 2026 Financial Results (PR Newswire)
Feb-08-26 07:38AM	Dow 50,000 sets table for inflation data, delayed January jobs report: What to watch this week (Yahoo Finance)
Feb-07-26 10:03PM	BD Earnings: What To Look For From BDX (StockStory)
10:45AM	Loading…
Feb-05-26 10:45AM	Can Sustained Product Demand Drive BDX Stock Before Q1 Earnings? (Zacks)
Feb-04-26 09:15AM	Countdown to Becton Dickinson (BDX) Q1 Earnings: A Look at Estimates Beyond Revenue and EPS (Zacks)
Feb-03-26 12:30PM	Citi bullish on Becton Dickinson after Life Sciences sale (Investing.com)
10:00AM	Staar Surgical (STAA) to Report Q4 Results: Wall Street Expects Earnings Growth (Zacks)
08:34AM	Piper Sandler Highlights Upcoming Segment Transition at Becton Dickinson (BDX) (Insider Monkey)
Feb-02-26 08:38PM	Becton, Dickinson and Company (BDX): A Bull Case Theory (Insider Monkey)
06:00PM	Steven Romick's Strategic Moves: A Closer Look at Becton Dickinson & Co (GuruFocus.com)
11:57AM	BD & Envetec Showcase Closed-Loop Recycling Solution for Lab Plastics (Zacks)
10:00AM	Earnings Preview: Becton Dickinson (BDX) Q1 Earnings Expected to Decline (Zacks)
Jan-31-26 11:37AM	Becton, Dickinson Shareholders Approve All Proposals at Annual Meeting, Recap Record FY2025 (MarketBeat)
Jan-29-26 06:50AM	BD and Envetec Demonstrate Closed-Loop Recycling Solution for Laboratory Plastics in Health Care (PR Newswire)
Jan-27-26 04:15PM	BD Board Declares Dividend, Authorizes 10 Million Additional Share Repurchases; BD Completed $250 Million Repurchase to Date in FY26 (PR Newswire)
11:47AM	BDX Introduces BD Research Cloud 7.0 for Advanced Flow Cytometry (Zacks)
11:40AM	BDX vs. SAUHY: Which Stock Is the Better Value Option? (Zacks)
09:40AM	Why Becton Dickinson (BDX) is a Top Value Stock for the Long-Term (Zacks)
09:37AM	Target upgraded, Stryker downgraded: Wall Street's top analyst calls (The Fly)
09:26AM	BD to Announce Financial Results for its First Quarter of Fiscal 2026 (PR Newswire)
09:25AM	Waters Shareholders Approve Combination with BD's Biosciences & Diagnostic Solutions Business (PR Newswire)
09:25AM	BD Announces Record Date for the Spin-Off of its Biosciences & Diagnostic Solutions Business (PR Newswire)
Jan-26-26 09:50AM	Why Becton Dickinson (BDX) is a Top Momentum Stock for the Long-Term (Zacks)
Jan-23-26 04:34PM	Stocks Finish Mostly Higher Despite a Plunge in Intel (Barchart)
06:50AM	BD Helps Scientists Advance Immunology and Cancer Research with AI-Powered Insights and Automation (PR Newswire)
Jan-22-26 10:43AM	BD and Ypsomed Expand Partnership to Target Growing Biologics Market (Zacks)
06:13AM	BD and Ypsomed develop new version of Neopak XtraFlow syringe (Medical Device Network)
Jan-21-26 11:43AM	BD Gets FDA 510(k) Approval for EnCor EnCompass Breast Biopsy System (Zacks)
06:50AM	BD and Ypsomed Expand Partnership to Address Rapidly Growing Biologics Market (PR Newswire)
Jan-15-26 12:38PM	Becton, Dickinson Wins FDA Clearance For Next-Gen Breast Biopsy Device, Launch Set For 2026 (Benzinga)
06:50AM	BD Receives FDA 510(k) Clearance for EnCor EnCompass Breast Biopsy and Tissue Removal System (PR Newswire)
Jan-14-26 06:50AM	BD Names Shawn Bevec as Senior Vice President of Investor Relations (PR Newswire)
06:00AM	BD invests $110m to expand US prefillable syringe production (Pharmaceutical Technology)
Jan-13-26 06:50AM	BD Announces $110 Million to Support U.S. Pharmaceutical Supply Chain for Biologic Drugs (PR Newswire)
Jan-12-26 04:15PM	BD To Host Virtual 2026 Annual Meeting of Shareholders (PR Newswire)
Jan-08-26 12:32PM	What to Expect From Becton, Dickinson and Company's Next Quarterly Earnings Report (Barchart)
09:40AM	Are You a Value Investor? This 1 Stock Could Be the Perfect Pick (Zacks)
Jan-05-26 06:50AM	BD Marks Milestone with First Phasix Hernia Prevention Case in Greece and Over 85% Enrollment in U.S. PREVENT Trial (PR Newswire)
Jan-02-26 06:21PM	RBC Sees Durable Growth Profile at Becton Dickinson (BDX), Raises Target (Insider Monkey)
Dec-26-25 07:53AM	Hologic's GYN Surgical Segment Looks Poised for Long-Term Growth (Zacks)
Dec-24-25 01:10PM	Top Stock Reports for AbbVie, Coca-Cola & Chevron (Zacks)
08:46AM	Are Options Traders Betting on a Big Move in BD Stock? (Zacks)
Dec-22-25 12:12PM	BD and Penn Institute Ink Collaboration to Advance Immunotherapy (Zacks)
Dec-19-25 09:40AM	Why This 1 Value Stock Could Be a Great Addition to Your Portfolio (Zacks)
Dec-18-25 09:50AM	Why Becton Dickinson (BDX) is a Top Momentum Stock for the Long-Term (Zacks)
06:50AM	BD and Penn Institute for Immunology and Immune Health Collaborate to Advance Immunotherapy through Flow Cytometry (PR Newswire)
Dec-17-25 08:26AM	Hologic's Genius AI Detection Shows Value by Spotting Missed Cancers (Zacks)
Dec-16-25 11:37AM	BD Expands BD MAX With IVDR-Approved VIASURE Tests in Europe (Zacks)
Dec-15-25 04:40PM	BD Expands BD MAX System Menu with New IVDR-Certified VIASURE Assays in Partnership with Certest Biotec (PR Newswire)
Dec-12-25 03:49AM	Baxter International Stock: Is BAX Underperforming the Health Care Sector? (Barchart)
Dec-11-25 07:44PM	Analyst Report: Becton, Dickinson and Company (Morningstar Research)
02:13AM	Morgan Stanley Highlights Positive Outlook for Becton, Dickinson (BDX) and the MedTech Sector (Insider Monkey)
Dec-10-25 08:40PM	Analyst Report: Becton, Dickinson and Company (Morningstar Research) +5.07%
Dec-07-25 11:02PM	3 Reasons BDX is Risky and 1 Stock to Buy Instead (StockStory)
Dec-05-25 11:53AM	BD Stock Up Post Tie-Up to Expand Hazardous Drug Contamination Testing (Zacks)
Dec-04-25 10:23AM	Hologic's BCI Test Shows Growing Impact in Endocrine Therapy Decisions (Zacks)
06:50AM	BD and ChemoGLO Collaborate to Expand Hazardous Drug Contamination Testing for Health Care Facilities and Laboratories (PR Newswire)
Dec-03-25 06:50AM	BD Launches New Cell Analyzer Configurations to Bring Cutting-Edge Capabilities to Labs of All Sizes (PR Newswire)
Dec-01-25 04:29AM	Is Becton, Dickinson and Company Stock Underperforming the Nasdaq? (Barchart)
Nov-25-25 09:40AM	Here's Why Becton Dickinson (BDX) is a Strong Value Stock (Zacks)
Nov-24-25 09:50AM	Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick (Zacks)
06:50AM	BD Surgiphor Surgical Wound Irrigation System Expands to Europe to Help Hospitals Improve Patient Safety (PR Newswire)
Nov-21-25 07:13AM	Hologic's GYN Surgical Delivers a Standout Quarter: What's Behind It? (Zacks)
Nov-19-25 08:27AM	What Makes Becton Dickinson (BDX) a Good Long-Term Investment? (Insider Monkey)
Nov-17-25 11:40PM	3 Healthcare Stocks We Approach with Caution (StockStory)
04:30PM	BD Appoints Robert Huffines and Jacqueline Wright to Board of Directors (PR Newswire)
09:23AM	Here's Hinde Group's Investment Thesis for Becton, Dickinson and Company (BDX) (Insider Monkey)
09:14AM	Aristotle Atlantic's Core Equity Strategy Sold Becton, Dickinson and Company (BDX) Due to Recent Earnings Weakness (Insider Monkey)
06:50AM	BD Onclarity HPV Assay for BD COR and BD Viper LT Systems Receive WHO Prequalification (PR Newswire)
Nov-13-25 06:01PM	First Pacific Advisors' Strategic Moves: Becton Dickinson & Co Takes Center Stage (GuruFocus.com)
02:00PM	BDX Unveils Portable PureWick System for On-the-Go Incontinence Care (Zacks)
06:55AM	What Are Wall Street Analysts' Target Price for Becton, Dickinson and Company Stock? (Barchart)
06:50AM	Duncan Regional Hospital Becomes First in U.S. to Implement BD Alaris EMR Infusion Interoperability with MEDITECH (PR Newswire)

Becton, Dickinson & Co. is a global medical technology company, which engages in the development, manufacture, and sale of medical supplies, devices, laboratory equipment, and diagnostic products. It operates through the following segments: BD Medical, BD Life Sciences, and BD Interventional. The BD Medical segment produces medical technologies and devices that are used to help improve healthcare delivery. The BD Life Sciences segment provides products for the safe collection and transport of diagnostics specimens, instruments, and reagent systems to detect infectious diseases, healthcare-associated infections, and cancers. The BD Interventional segment offers vascular, urology, oncology, and surgical specialty products to hospitals, ambulatory surgery centers, individual healthcare professionals, extended care facilities, alternate site facilities, and patients via its Homecare business. The company was founded by Maxwell W. Becton and Fairleigh S. Dickinson in 1897 and is headquartered in Franklin Lakes, NJ.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Feld Michael	EVP, CRO & Pres. Life Sciences	Jan 26 '26	Sale	202.73	75	15,205	16,431	Jan 28 09:46 AM
MICHAEL FELD	Officer	Jan 26 '26	Proposed Sale	201.79	75	15,134		Jan 26 04:31 PM
Garrison Michael David	EVP & Pres Med.Essntl&BioPharm	Jan 15 '26	Option Exercise	167.91	3,054	512,797	16,159	Jan 16 03:43 PM
Garrison Michael David	EVP & Pres Med.Essntl&BioPharm	Jan 15 '26	Sale	207.46	1,610	334,005	12,095	Jan 16 03:43 PM
MICHAEL GARRISON	Officer	Jan 15 '26	Proposed Sale	207.42	1,610	333,946		Jan 15 04:22 PM
MICHAEL FELD	Officer	Dec 26 '25	Proposed Sale	196.12	74	14,513		Dec 29 07:48 AM
Feld Michael	EVP, CRO & Pres. Life Sciences	Dec 26 '25	Sale	196.08	74	14,510	16,506	Dec 29 07:00 AM
Garrison Michael David	EVP & Pres Med.Essntl&BioPharm	Dec 17 '25	Sale	196.03	629	123,303	13,105	Dec 17 08:12 PM
MICHAEL GARRISON	Officer	Dec 17 '25	Proposed Sale	196.39	629	123,529		Dec 17 04:24 PM
Feld Michael	EVP, CRO & Pres. Life Sciences	Dec 01 '25	Sale	193.36	75	14,502	16,580	Dec 02 06:25 PM
MICHAEL FELD	Officer	Dec 01 '25	Proposed Sale	194.02	75	14,552		Dec 01 04:18 PM
SCOTT BERTRAM L	Director	Nov 07 '25	Sale	176.58	217	38,318	35,816	Nov 07 05:36 PM
BERTRAM SCOTT	Officer	Nov 07 '25	Proposed Sale	176.58	217	38,318		Nov 07 04:32 PM
Feld Michael	EVP & President, Life Sciences	Oct 27 '25	Sale	186.01	57	10,603	8,245	Oct 28 11:58 AM
MICHAEL FELD	Officer	Oct 27 '25	Proposed Sale	185.83	57	10,592		Oct 27 04:26 PM
Feld Michael	EVP & President, Life Sciences	Sep 26 '25	Sale	181.03	58	10,500	8,302	Sep 29 04:58 PM
MICHAEL FELD	Officer	Sep 26 '25	Proposed Sale	180.59	58	10,474		Sep 26 04:29 PM
Fraser Claire	Director	Sep 10 '25	Sale	187.50	917	171,938	22,226	Sep 11 12:36 PM
Fraser Claire	Director	Sep 10 '25	Proposed Sale	187.42	917	171,862		Sep 10 03:42 PM
Feld Michael	EVP & President, Life Sciences	Aug 22 '25	Sale	197.99	57	11,285	8,360	Aug 26 03:41 PM
MICHAEL FELD	Officer	Aug 22 '25	Proposed Sale	196.63	57	11,208		Aug 22 04:38 PM
HAYES GREGORY	Director	Aug 11 '25	Buy	191.57	5,250	1,005,742	6,046	Aug 11 04:15 PM
Fraser Claire	Director	Aug 08 '25	Sale	192.30	863	165,955	23,143	Aug 08 06:56 PM
Fraser Claire	Director	Aug 08 '25	Proposed Sale	192.21	863	165,880		Aug 08 02:32 PM
Garrison Michael David	EVP & President, Medical	Jul 18 '25	Option Exercise	147.68	6,360	939,245	11,247	Jul 22 05:29 PM
Garrison Michael David	EVP & President, Medical	Jul 18 '25	Sale	180.29	1,185	213,645	4,887	Jul 22 05:29 PM
MICHAEL GARRISON	Officer	Jul 18 '25	Proposed Sale	180.90	1,185	214,366		Jul 18 04:48 PM
Shan David	EVP and Chief ISC Officer	Jun 02 '25	Sale	171.19	1,166	199,608	4,575	Jun 02 06:44 PM
DAVID SHAN	Officer	Jun 02 '25	Proposed Sale	172.59	1,166	201,240		Jun 02 04:24 PM
Garrison Michael David	EVP & President, Medical	Apr 09 '25	Sale	197.28	479	94,497	4,887	Apr 10 01:56 PM
MICHAEL GARRISON	Officer	Apr 09 '25	Proposed Sale	200.83	479	96,198		Apr 09 04:16 PM
Byrd Richard	EVP & President Interventional	Mar 18 '25	Sale	230.00	459	105,570	6,952	Mar 19 01:55 PM
RICHARD BYRD	Officer	Mar 18 '25	Proposed Sale	227.83	459	104,574		Mar 18 04:33 PM
Byrd Richard	EVP & President Interventional	Mar 12 '25	Sale	224.91	1,940	436,325	7,411	Mar 13 01:03 PM
RICHARD BYRD	Officer	Mar 12 '25	Proposed Sale	224.92	1,940	436,345		Mar 12 04:22 PM

HALO

Halozyme Therapeutics Inc

BDX

Becton Dickinson & Co

Upgrade your FINVIZ experience